The treatment Xultophy, which combines Novo Nordisk's long-acting insulin Tresiba with the GLP-1 analog Victoza, is now headed to the Chinese market.
In Wednesday's report for the third quarter of the year, Novo Nordisk reports that the Chinese health authority, China National Products Administration (NMPA), has approved of the injection therapy for type 2 diabetes.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.